Abstract: This disclosure relates to liquid dispersion compositions that are suitable to provide absorbent materials (e.g., an absorbent coating), and methods of preparing the compositions and absorbent materials thereof.

Abstract: A wireless transmit/receive unit (WTRU) may comprise a processor. The processor may be configured to receive (e.g., via broadcast) configuration information indicating a time that a same-PCI satellite switch may occur. In one or more examples, the WTRU may transmit assistance information prior to the same-PCI satellite switch. The assistance information may, for example, include a re-synchronization duration, capabilities to synchronization procedures, and/or a time indication for resuming TX and/or RX. The WTRU may receive configuration information for satellite re-synchronization. The WTRU may perform the same-PCI satellite switch to the second satellite, for example, based on the configuration information indicating the time for the same-PCI satellite switch. In performing the same-PCI satellite switch, the WTRU may start a resynchronization gap, suspend UL TX and/or DL RX, and/or perform re-synchronization procedure(s).

Abstract: A wireless transmit/receive unit (WTRU) may determine a first set of beams and a second set of beams, that a respective quality of each beam in the first set of beams is less than a predetermined quality value, and that a beam that is in the second set of beams and not in the first set of beams has a quality that is equal to or greater than the predetermined quality value. The WTRU may select the beam that is in the second set of beams and not in the first set of beams and whose quality is equal to or greater than the predetermined quality value, for a BFR and send a message that indicates the selected beam for the BFR to abase station (e.g., a gNodeB). The WTRU may receive a message comprising the selected beam from the gNodeB.

Abstract: A system (1600) and method (960) for utilizing data from on-vehicle and off-vehicle sources to identify problematic devices and to execute automated mitigations is disclosed herein. The system (1620) comprises assigning authority engine (1105) for a vehicle (1000), a device (110) for the vehicle (1000), one or more databases (1615), and more or more cloud sources (1175). The assigning authority engine (1105) is configured to analyze the data based on a plurality of pre-defined patterns to identify a malfunctioning device and to transmit a mitigation strategy for the malfunctioning device.

Abstract: A system for screening of pathogens or gene differences includes first and second screening modes and a source of electromagnetic radiation for illuminating a plurality of samples. The source of electromagnetic radiation has a selectable illumination property. The system also may include a detector for detecting electromagnetic radiation transmitted through or emitted by the plurality of samples with the detector having a selectable detection property. The system may be arranged for concurrent operation in the first and the second mode. The first screening mode may be a fluorometric screening mode and the second optional screening mode may be a colorimetric screening mode.

Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-8 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.

Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

Abstract: This invention provides for a flow synthesis process for producing sulfonylurea compounds of formula (1), including glipizide and glibenclamide, and pharmaceutically acceptable salts thereof.

Abstract: A system (1600) and method (960) for utilizing data from on-vehicle and off-vehicle sources to identify problematic devices and to execute automated mitigations is disclosed herein. The system (1620) comprises assigning authority engine (1105) for a vehicle (1000), a device (110) for the vehicle (1000), one or more databases (1615), and more or more cloud sources (1175). The assigning authority engine (1105) is configured to analyze the data based on a plurality of pre-defined patterns to identify a malfunctioning device and to transmit a mitigation strategy for the malfunctioning device.

Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.

Abstract: An automated analyser for high-throughput assay testing for the presence of a biological or biochemical substance includes a plurality of sample process stations to receive analysis vessels and perform one or more processing or analysis steps on samples retained in the analysis vessels and including at least an incubation station to receive a plurality of the analysis vessels, provide illumination to each sample of each analysis vessel in the incubation field, and maintain the plurality of analysis vessels at predetermined incubation temperatures. The analyser includes an analysis vessel transfer system to transfer analysis vessels between the process stations, an imaging system to image illuminated samples in the analysis vessels retained in the incubation field, and a resource controller.

Abstract: The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.

Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

Abstract: A multistep continuous flow synthesis method for the manufacture of isonicotinyl-hydrazide (Isoniazid) comprising reacting 4-cyano pyridine with NaOH at a specified molar ratio and temperature range to produce the intermediate isonicotinamide, which intermediate is reacted with hydrazine hydrate, without isolation thereof, at a specified molar ratio and temperature range to produce isonicotinyl-hydrazide (Isoniazid) in a yield greater than about 90%.

Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.

Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

Abstract: A system (1600) and method (960) for utilizing data from on-vehicle and off-vehicle sources to identify problematic devices and to execute automated mitigations is disclosed herein. The system (1620) comprises assigning authority engine (1105) for a vehicle (1000), a device (110) for the vehicle (1000), one or more databases (1615), and more or more cloud sources (1175). The assigning authority engine (1105) is configured to analyze the data based on a plurality of pre-defined patterns to identify a malfunctioning device and to transmit a mitigation strategy for the malfunctioning device.

Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inter alia autoinflammatory and autoimmune diseases and cancers.

Abstract: This invention provides for a flow synthesis process for producing Oseltamivir and pharmaceutically acceptable salts thereof from shikimic acid in particular but not exclusively to a flow synthesis process for producing Oseltamivir phosphate from shikimic acid in a nine-step flow synthesis that provides for superior reaction times and product yields compared to known methods.